Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Tesamorelin
Growth Hormone Secretagogues
Molecular Dossier
- Rank Index: 11
- Status: FDA Approved
- What does this mean?
- Molecular Structure: 44 Amino Acid Analog
About Tesamorelin
GHRH analog researched for reducing visceral adipose tissue (VAT).
Clinical Focus
Visceral Fat Reduction
Archival Aliases
Egrifta, TH9507
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is tesamorelin approved for?
Tesamorelin (Egrifta/Egrifta SV) is FDA-approved for the reduction of excess visceral abdominal fat in HIV-positive patients who develop lipodystrophy (fat redistribution) as a side effect of antiretroviral therapy. It is the only FDA-approved GHRH analog and represents the strongest clinical evidence base for any growth hormone secretagogue in visceral fat reduction.
How does tesamorelin reduce visceral fat?
Tesamorelin stimulates pulsatile GH release, which in turn elevates IGF-1. Elevated GH directly promotes lipolysis (fat breakdown) in adipocytes, with visceral adipose tissue being particularly sensitive to GH-mediated fat mobilization. Clinical trials show a 15-20% reduction in visceral adipose tissue area (VAT) as measured by CT scan after 6-12 months of treatment.
Does tesamorelin work for non-HIV visceral fat?
Phase 3 data was conducted in HIV patients, making that the approved indication. However, the mechanism of visceral fat reduction is not specific to HIV pathophysiology — it relates to GH deficiency-driven visceral fat accumulation, which occurs broadly with aging. Off-label research in non-HIV populations shows similar VAT reduction, and tesamorelin is among the most-studied secretagogues in body composition optimization research.
What dose is used in tesamorelin research?
The FDA-approved dose is 2mg subcutaneously once daily. This is the dose used in all published clinical trials. It is typically administered at bedtime on an empty stomach to align with the natural nocturnal GH pulse. Research protocols exploring body composition optimization in non-HIV contexts use the same 2mg dose.
How does tesamorelin compare to CJC-1295?
Tesamorelin is a full-length GHRH analog (44 amino acids) with a modification that extends its half-life to approximately 20 minutes compared to native GHRH. CJC-1295 is a shortened version (30 amino acids, Mod GRF 1-29) with various modifications. Tesamorelin has far more human clinical trial data supporting its use. CJC-1295 with DAC produces more prolonged GH elevation. Both are structurally related and mechanistically similar.
What improvements beyond fat loss does tesamorelin produce?
Beyond VAT reduction, clinical trials document: improved lipid profiles (reduced triglycerides, favorable HDL changes), improvements in cognitive function in older adults (separate clinical trial data), enhanced physical performance, and improved quality of life scores. IGF-1 levels also normalize, which has downstream effects on protein synthesis, bone density, and cellular repair.
Is there any cognitive benefit research for tesamorelin?
Yes — an independently conducted clinical trial published in JAMA Psychiatry (2019) found that daily tesamorelin in older adults with Mild Cognitive Impairment (MCI) produced significant improvements in verbal memory and executive function compared to placebo. The mechanism is thought to involve IGF-1's neuroprotective effects and its role in hippocampal neurogenesis, opening research interest in tesamorelin as a cognitive longevity intervention.
What happens when tesamorelin is stopped?
Fat redistribution begins reversing within 3-6 months of cessation, with VAT returning toward baseline. This is consistent with tesamorelin's mechanism as a GH secretagogue rather than a direct fat cell intervention — it requires continued stimulation to maintain GH-mediated lipolysis. This makes it a chronic management compound for visceral fat rather than a one-time treatment.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | 44 Amino Acid Analog |
| Primary Pathway | Growth Hormone Secretagogues |
| Research Phase | FDA Approved |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-04-10